DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
DS-5565 is an investigational drug.
There have been 12 clinical trials for DS-5565. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.
The most common disease conditions in clinical trials are Neuralgia, Diabetic Neuropathies, and Myofascial Pain Syndromes. The leading clinical trial sponsors are Daiichi Sankyo Inc., Daiichi Sankyo Co., Ltd., and INC Research.
There are seven US patents protecting this investigational drug and one hundred and twenty-three international patents.
Recent Clinical Trials for DS-5565
|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain||Daiichi Sankyo Co., Ltd.||Phase 3|
|Study of Mirogabalin for Central Neuropathic Pain||Daiichi Sankyo Co., Ltd.||Phase 3|
|DS-5565 Phase III Study for Renal Impairment in Japanese Subjects||CMIC Co, Ltd. Japan||Phase 3|
Top disease conditions for DS-5565
Top clinical trial sponsors for DS-5565
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|DS-5565||Start Trial||Bicyclic .gamma.-amino acid derivative||Daiichi Sankyo Company, Ltd. (Tokyo, JP)||Start Trial|
|DS-5565||Start Trial||Method for producing bicyclic .gamma.-amino acid derivative||Daiichi Sankyo Company, Limited (Tokyo, JP)||Start Trial|
|DS-5565||Start Trial||Methods for producing bicyclic compounds via claisen rearrangements||Daiichi Sankyo Company, Limited (Tokyo, JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|